Corcept Therapeutics (NASDAQ:CORT) Stock Price Crosses Below 200 Day Moving Average on Insider Selling

Corcept Therapeutics Incorporated (NASDAQ:CORT)’s stock price passed below its 200-day moving average during trading on Thursday following insider selling activity. The stock has a 200-day moving average of $75.47 and traded as low as $71.52. Corcept Therapeutics shares last traded at $71.63, with a volume of 1,507,614 shares changing hands.

Specifically, insider Roberto Vieira sold 8,333 shares of the firm’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $80.89, for a total value of $674,056.37. Following the completion of the transaction, the insider owned 3,946 shares of the company’s stock, valued at approximately $319,191.94. This trade represents a 67.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Sean Maduck sold 13,159 shares of the firm’s stock in a transaction on Tuesday, November 3rd. The shares were sold at an average price of $82.25, for a total transaction of $1,082,327.75. Following the completion of the transaction, the insider directly owned 9,938 shares of the company’s stock, valued at approximately $817,400.50. This trade represents a 56.97% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In other Corcept Therapeutics news, insider Sean Maduck sold 11,841 shares of Corcept Therapeutics stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $81.42, for a total value of $964,094.22. Following the sale, the insider directly owned 9,938 shares in the company, valued at approximately $809,151.96. The trade was a 54.37% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Analyst Ratings Changes

Several equities analysts have recently weighed in on CORT shares. Wall Street Zen upgraded Corcept Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 1st. Piper Sandler reaffirmed an “overweight” rating and issued a $173.00 target price (up from $165.00) on shares of Corcept Therapeutics in a research report on Wednesday. Wolfe Research lowered Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $50.00 target price on the stock. in a report on Monday, July 27th. Truist Financial started coverage on Corcept Therapeutics in a research report on Tuesday, August 18th. They set a “buy” rating and a $164.00 price target for the company. Finally, Canaccord Genuity Group raised their price target on Corcept Therapeutics from $135.00 to $150.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. Five analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $139.50.

Key Stories Impacting Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Third-quarter revenue climbed 64% year over year to about $340.5 million, while earnings of $1.01 per share beat estimates. Higher Korlym sales and growing Lifyorli uptake contributed to the results. Article: CORT’s Q3 Earnings Beat
• Positive Sentiment: Piper Sandler reaffirmed its “overweight” rating and raised its price target to $173 from $165. Article: Piper Sandler rating
• Neutral Sentiment: Corcept is awaiting a December 17 FDA decision on relacorilant and has outlined a long-term opportunity of $3 billion to $5 billion in Cushing’s revenue by 2030; both depend on regulatory and commercial success. Article: Relacorilant decision and revenue target
• Negative Sentiment: Shares have faced pressure despite the earnings beat as investors focused on company guidance. HC Wainwright also lowered its Q1 2027 EPS estimate to $0.60 from $0.74, although it kept a Buy rating and $165 price target. Article: Shares fall on guidance
• Negative Sentiment: Two insiders reported sizable sales: Roberto Vieira sold 8,333 shares, reducing his position by about 68%, while Sean Maduck sold shares in two transactions that cut his holdings by more than half. Insider sales can raise concerns, though they do not necessarily indicate a change in company prospects. Article: Corcept insider sale

Corcept Therapeutics Stock Down 9.6%

The stock has a market cap of $7.84 billion, a price-to-earnings ratio of 56.40 and a beta of 0.54. The business’s 50 day simple moving average is $108.46 and its 200 day simple moving average is $75.47.

Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings data on Tuesday, November 3rd. The biotechnology company reported $1.01 EPS for the quarter, beating analysts’ consensus estimates of $0.84 by $0.17. The company had revenue of $340.47 million during the quarter, compared to the consensus estimate of $339.12 million. Corcept Therapeutics had a net margin of 16.53% and a return on equity of 22.56%. The company’s quarterly revenue was up 64.0% on a year-over-year basis. During the same quarter last year, the firm posted $0.16 EPS. Equities research analysts forecast that Corcept Therapeutics Incorporated will post 1.83 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Corcept Therapeutics

Several hedge funds have recently bought and sold shares of CORT. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in Corcept Therapeutics during the second quarter worth about $27,000. State of Wyoming raised its stake in Corcept Therapeutics by 29.5% in the first quarter. State of Wyoming now owns 816 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 186 shares during the period. Provenance Wealth Advisors LLC bought a new stake in Corcept Therapeutics in the third quarter valued at approximately $38,000. Gould Capital LLC raised its stake in Corcept Therapeutics by 66.7% in the first quarter. Gould Capital LLC now owns 1,000 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 400 shares during the period. Finally, Fulcrum Asset Management LLP lifted its position in shares of Corcept Therapeutics by 520.7% in the third quarter. Fulcrum Asset Management LLP now owns 571 shares of the biotechnology company’s stock valued at $66,000 after buying an additional 479 shares during the last quarter. 93.61% of the stock is currently owned by institutional investors and hedge funds.

About Corcept Therapeutics

Corcept Therapeutics Incorporated (NASDAQ:CORT) is a commercial-stage biopharmaceutical company focused on developing medicines that selectively modulate the glucocorticoid receptor. The company’s research is based on the role of excess cortisol in metabolic, psychiatric, oncologic and other serious medical conditions.

Corcept’s primary marketed product is Korlym (mifepristone), an oral glucocorticoid receptor antagonist approved in the United States to control hyperglycemia secondary to endogenous Cushing’s syndrome in adults with type 2 diabetes or glucose intolerance who are not candidates for surgery or have not responded adequately to surgery.